Fekade B Sime
@b_fekade
Followers
87
Following
123
Media
1
Statuses
29
Joined June 2018
Stability of tigecycline in elastomeric devices for OPAT - Tigecycline meets the 🇬🇧 YCD criteria of ≤5% degradation limit. Fantastic collaboration with 🌍 colleagues @jasonroberts_pk @b_fekade @raseaton66 @BSACandJAC
academic.oup.com
AbstractBackground. Tigecycline is increasingly being considered in outpatient parenteral antimicrobial therapy (OPAT) programmes given its spectrum of act
0
8
15
Our article: https://t.co/KrOPQnlLQX… has been selected for inclusion in the Best of Journal of Antimicrobial Chemotherapy 2024. @b_fekade @jasonroberts_pk @CRE_RESPOND #UQCCR @UQMedicine @UQ_News
https://t.co/UjO3A8US6g
academic.oup.com
As we usher in the new year, Dr Peter Donnelly, the Editor-in-Chief of BSAC’s Journal of Antimicrobial Chemotherapy (JAC) would like to warmly thank all authors
0
3
11
‘By standardising stability testing guidelines, we can broaden treatment options for patients with serious infections, improve clinical outcomes, advance antimicrobial stewardship, and reduce healthcare costs.’ https://t.co/DGLKKzQgzO
@b_fekade @jasonroberts_pk @CRE_RESPOND
bsac.org.uk
0
5
7
Is it time for global harmonization of opat drug stability testing frameworks? Great to collaborate with @jasonroberts_pk @b_fekade @CRE_RESPOND @raseaton66 @BSACandJAC & many more - onto the next step!
academic.oup.com
Abstract. Antimicrobial stability is an important consideration for treatment planning and service delivery in outpatient parenteral antimicrobial therapy
1
6
16
🆕️🔥State of the art review article #JAC 🌟s @jasonroberts_pk @b_fekade @MGilchrist123 Current Practices and challenges of outpatient parenteral antimicrobial therapy #OPAT #IDXposts #bookmark Great tables🎯 https://t.co/5iAyfG1M5d
academic.oup.com
Abstract. Extended hospitalization for infection management increases inpatient care costs and the risk of healthcare-associated adverse events, including
0
41
79
In OPAT settings, continuous 12 h CZA infusion may be possible in territories where degradation of ≤10% is deemed acceptable But avoid prolonged fridge storage (>72h) to keep overall sequential degradation to <10%: https://t.co/OHkaBjMFsy
@b_fekade @jasonroberts_pk #JACAMRNews
academic.oup.com
AbstractObjectives. To evaluate the stability of ceftazidime/avibactam in elastomeric infusers, utilizing the UK’s Yellow Cover Document (YCD) stability te
0
6
8
Great to see this - Evaluation of stability of ceftazidime/avibactam in elastomeric infusion devices used for OPAT. 🇬🇧 & 🇦🇺 partnership in this space continues @b_fekade @jasonroberts_pk @raseaton66 @jamiesonce & more
academic.oup.com
AbstractObjectives. To evaluate the stability of ceftazidime/avibactam in elastomeric infusers, utilizing the UK’s Yellow Cover Document (YCD) stability te
1
6
21
You're invited to an exciting 3-day workshop on Antimicrobial Optimisation: Population pharmacokinetic modeling and dosing software. 30 places available Reg: https://t.co/4mbfYUV92Q
@jasonroberts_pk @DocJamesPollard @legg_wamy @davidantibiotic @IATDMCT @NCICancer @PattyMitre_
0
4
7
You're invited to an exciting 3-day workshop on Antimicrobial Optimisation: Population pharmacokinetic modeling and dosing software. 30 places available Reg: https://t.co/4mbfYUV92Q
@jasonroberts_pk
@DocJamesPollard
@legg_wamy
@SuzieParker_CMG
@IATDMCT
@NCICancer
@PattyMitre_
2
7
14
Join ISAC's Anti-Infective Pharmacology Working Group free of cost https://t.co/M3VHOjbAFk
0
1
0
Supported by @CRE_REDUCE , we published 33 papers on PK/PD of antimicrobials since 2019. Exting time as we transition to #CRE_RESPOND @jasonroberts_pk #Steategicretreat
0
3
16
Live Roundtable Discussion on Clinical Trials Targeting Antimicrobial Resistance with @davidantibiotic ,DR. Mo Yin and @davidlye70
0
2
3
Lots happening at CRE REDUCE in the next few months! Check out our upcoming education events https://t.co/h5rwdrRMHf!
@jasonroberts_pk
1
3
13
It’s very nice to “see” everyone at #ECCMID2021. I’m struck that despite the last 18/12, so little has changed in the #AMR world. We are good at describing the problem but seem to be less interested in radical thinking that is required to minimise the impact of AMR. 1/6
4
32
100
Hello OPAT / HITH/ IV@home communities - antibiotic stability question for you! What buffers are used in continuous abx infusions in your service. Poll below or feel free to reply with more information! @BSACandJAC @jamiesonce @jasonroberts_pk @b_fekade @UKCPAPIN
4
7
7
It would make sense that high aminoglycoside concentrations achieved in the lungs after nebulisation would optimise bacterial killing for patients with pneumonia. But why has it failed in clinical trials? One potential factor is the epithelial lining fluid
link.springer.com
Drugs in R&D - Even though nebulised administration of amikacin can achieve high epithelial lining fluid concentrations, this has not translated into improved patient outcomes in clinical...
1
5
12
Checkout my point of view on #COVID19Vaccine @AustralianCRS @UQHealth @UQPharmacy Thank you @WolframJoy for creating this beautiful graphic and @CRS_FG_NANO for this opportunity
0
7
42
[New Paper] Clinician checklist for assessing suitability of machine learning applications in healthcare
informatics.bmj.com
Machine learning algorithms are being used to screen and diagnose disease, prognosticate and predict therapeutic responses. Hundreds of new algorithms are being developed, but whether they improve...
0
17
27